Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $80.00

Enliven Therapeutics (NASDAQ:ELVN) had its target price upped by The Goldman Sachs Group from $67.00 to $80.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target points to a potential upside of 34.00% from the company’s current price.

Several other research analysts have also commented on ELVN. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Guggenheim started coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price on the stock. Mizuho boosted their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. JonesTrading increased their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $72.67.

Enliven Therapeutics Stock Down 2.3%

Shares of ELVN stock opened at $59.70 on Thursday. The firm has a market cap of $3.64 billion, a price-to-earnings ratio of -35.75 and a beta of 0.27. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32. The company’s 50 day moving average is $47.81 and its 200 day moving average is $39.29.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Analysts anticipate that Enliven Therapeutics will post -1.57 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the transaction, the chief financial officer owned 46,054 shares in the company, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 32,036 shares of company stock valued at $1,430,676. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after purchasing an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after purchasing an additional 80,506 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Enliven Therapeutics during the 1st quarter worth approximately $578,000. Legal & General Group Plc increased its holdings in shares of Enliven Therapeutics by 52.2% during the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after purchasing an additional 11,058 shares in the last quarter. Finally, Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.